How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

The Active Surveillance Study

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Health checks and monitoring — no treatment given
Type of study: Observational (no treatment given)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Active Surveillance (other)
How long the study runs: Study runs about 52 months (dates as stated)
About the drug or intervention: Active Surveillance — other: Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a.
Patient visit burden: Not specified by the sponsor

Type of study: Observing health over time
Ages: 18 Years and over
Who: Male
Number of participants: 200
Started: 2023-08-22
Last checked: 2026-02

Plain English Summary

What is this study?

• Testing a new treatment for prostate cancer
• Clinical study - 200 participants
• The Active Surveillance study is a prospective study developed to look at the association of biomarkers with PrCa presentation and progression among men on Active Surveillance and stratify it by their genetic risk

Who can take part?

• Ages 18 Years and over
• Diagnosed with prostate cancer
• Male only

Where?

• Sutton - Institute of Cancer Research and Royal Marsden Hospital
• Bristol - North Bristol NHS Trust
• London - The Royal Marsden Hospital
• Sutton - The Royal Marsden Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The Active Surveillance study is a prospective study developed to look at the association of biomarkers with PrCa presentation and progression among men on Active Surveillance and stratify it by their genetic risk. This study will also investigate the incidence and progression by differing genetic risks.

More detail

This prospective study will look at the association of biomarkers with PrCa presentation and progression among men on Active Surveillance and stratify it by their genetic risk. This study will also investigate the incidence and progression by differing genetic risks. The study will review the serial PSA and imaging data for men in AS comparing and contrasting the men of known higher genetic risk for PrCa with those without a known higher genetic risk. Additionally, the study aims to collect samples to investigate the profile of plasma, serum, urine, stool, and saliva (or DNA from blood) biomarkers in men at a higher genetic risk of PrCa, who have been diagnosed with low risk PrCa and are undergoing Active Surveillance. It will also review the association of specific genetic profiles and biomarkers (biological samples - plasma, serum, urine, stool and saliva - where possible, DNA from blood will be used instead of saliva samples). These markers will be compared and contrasted with samples from men with no known increased genetic risk for PrCa. The study aims to recruit a total of 200 men with low grade PrCa, aged ≥18 into two cohorts (i.e. men on AS who are known to be at higher genetic risk and those on AS with no known increased genetic risk of PrCa. Patients will be identified through urology clinics at the Royal Marsden Hospital and North Bristol NHS Trust. These will be men who are already registered at either the Royal Marsden Hospital or North Bristol NHS Trust and undergoing active surveillance (as determined by the MDT) will be given a patient information sheet. This explains the study in lay terms and gives the contact details for the relevant research team.

Prostate Cancer

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: Male only

Biomarkers mentioned

with a positiveBRCA1BRCA2

What the study is looking for

✓Inclusion Criteria
✓Men ≥18 years old under the care of an Active Surveillance clinic.
✓Known diagnosis of PrCa, deemed suitable for Active surveillance at multi-disciplinary meeting (MDT).
✓Men at genetically higher PrCa risk who are either:
✓(1) Men of any ancestry with a positive family history of PrCa defined as:

See the full criteria

Inclusion Criteria * Men ≥18 years old under the care of an Active Surveillance clinic. * Known diagnosis of PrCa, deemed suitable for Active surveillance at multi-disciplinary meeting (MDT). * Men at genetically higher PrCa risk who are either: (1) Men of any ancestry with a positive family history of PrCa defined as: * Having a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years * Having two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years * Having three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age Or (2) Men of Black African or Black African-Caribbean ancestry defined as: * Both parents and all 4 grandparents from that origin Or (3) Men of any ancestry with a pathogenic mutation in a gene thought to cause a higher risk of prostate cancer: (including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in appendix A) Or (4) Men of any ancestry with a high genetic risk (common and/or rare variants) for PrCa resulting in a RR of ≥2 of PrCa * Men of any ancestry with no known high risk genetic factors who have been diagnosed with low grade PrCa and deemed suitable for Active Surveillance at multi-disciplinary meeting (control group) as defined in the 4 criteria above. * Who performance status 0-2 * Absence of any psychological, familial, sociological, or geographical situation potentially hampering compliance with the study protocol and follow-up schedule. Exclusion Criteria * No PrCa diagnosis * PrCa diagnosis that is not deemed suitable for active surveillance at multi-disciplinary meeting * Any significant psychological conditions that may be worsened or exacerbated by participation in the study